(HRTS) Tema Cardiovascular - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • • Health
HRTS: GLP-1, Cardiovascular, Metabolic, Diabetes, Obesity, Heart
The Tema Cardiovascular and Metabolic ETF (NASDAQ:HRTS) is a non-diversified exchange-traded fund designed to focus on companies advancing treatments for cardiovascular and metabolic diseases, particularly those leveraging GLP-1 receptor agonists. Under normal market conditions, the fund allocates at least 80% of its net assets to publicly traded firms generating at least 50% of their revenue from products or services related to GLP-1 therapies or cardiovascular/metabolic disease treatments, as defined by the CDC. The portfolio typically holds between 15 and 100 companies, reflecting its targeted approach to the sector.
As of the latest data, the fund has an average trading volume of 19,062 shares over 20 days, with a last price of $30.81. Its short-term moving average (SMA 20) stands at $30.46, slightly below the current price, while the SMA 50 is at $29.89, indicating recent upward momentum. The SMA 200 is at $32.12, suggesting the fund has been trading below its longer-term average. The Average True Range (ATR) of 0.38 reflects relatively low volatility in recent trading sessions.
With assets under management (AUM) of $64.34 million, the fund is modestly sized within the ETF universe, allowing for targeted exposure to a niche segment of the healthcare sector.
Overall, the fund is projected to trade within a narrow range, with upside potential driven by positive developments in the GLP-1 and cardiovascular/metabolic disease treatment space. The 3-month forecast suggests a price range of $30.00 to $32.00, supported by its current technical and fundamental backdrop.
Additional Sources for HRTS ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HRTS ETF Overview
| Market Cap in USD | 64m |
| Category | Health |
| TER | 0.75% |
| IPO / Inception | 2023-11-20 |
HRTS ETF Ratings
| Growth 5y | 4.58% |
| Fundamental | - |
| Dividend | 12.5% |
| Rel. Strength Industry | -16.9 |
| Analysts | - |
| Fair Price Momentum | 26.72 USD |
| Fair Price DCF | - |
HRTS Dividends
| Dividend Yield 12m | 1.52% |
| Yield on Cost 5y | 1.79% |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 100.0% |
HRTS Growth Ratios
| Growth Correlation 3m | 31.4% |
| Growth Correlation 12m | -43.7% |
| Growth Correlation 5y | -0.1% |
| CAGR 5y | 9.26% |
| CAGR/Max DD 5y | 0.49 |
| Sharpe Ratio 12m | 0.19 |
| Alpha | -18.86 |
| Beta | 0.88 |
| Volatility | 19.78% |
| Current Volume | 7.2k |
| Average Volume 20d | 6.5k |
As of March 14, 2025, the stock is trading at USD 29.45 with a total of 7,237 shares traded.
Over the past week, the price has changed by -3.49%, over one month by -1.99%, over three months by -3.22% and over the past year by -11.12%.
Neither. Based on ValueRay Analyses, Tema Cardiovascular is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 4.58 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HRTS as of March 2025 is 26.72. This means that HRTS is currently overvalued and has a potential downside of -9.27%.
Tema Cardiovascular has no consensus analysts rating.
According to ValueRays Forecast Model, HRTS Tema Cardiovascular will be worth about 29.6 in March 2026. The stock is currently trading at 29.45. This means that the stock has a potential upside of +0.65%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 29.6 | 0.6% |